Ignite Creation Date:
2025-12-24 @ 9:55 PM
Ignite Modification Date:
2025-12-25 @ 7:34 PM
Study NCT ID:
NCT00216632
Status:
COMPLETED
Last Update Posted:
2012-12-07
First Post:
2005-09-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
Sponsor:
Janssen Pharmaceutica N.V., Belgium
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-03
Start Date Type:
None
Primary Completion Date:
2007-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2007-07
Completion Date Type:
ACTUAL
First Submit Date:
2005-09-13
First Submit QC Date:
None
Study First Post Date:
2005-09-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-12-06
Last Update Post Date:
2012-12-07
Last Update Post Date Type:
ESTIMATED